在接受依鲁替尼治疗的慢性淋巴细胞白血病（CLL）患者中进行氘代水标记：白血病细胞动力学与IGHV、ZAP-70和微小残留病（MRD）相关。
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD.
作者信息
Kim Ekaterina, Chen Shih-Shih, Sivina Mariela, Hwang Hyunsoo, Huang Xuelin, Ferrajoli Alessandra, Jain Nitin, Wierda William G, Wodarz Dominik, Chiorazzi Nicholas, Burger Jan A
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY.
出版信息
Blood. 2024 Dec 19;144(25):2678-2681. doi: 10.1182/blood.2024025683.
Deuterated ("heavy") water labeling in patients with chronic lymphocytic leukemia (CLL) demonstrates that IGHV unmutated and ZAP-70+ patients have higher blood and tissue CLL death rates on ibrutinib therapy, resulting in lower measurable residual disease levels with long-term ibrutinib treatment. This trial was registered at www.clinicaltrials.gov as #NCT01752426.
对慢性淋巴细胞白血病（CLL）患者进行的氘代（“重”）水标记显示，在接受依鲁替尼治疗时，IGHV未突变且ZAP-70阳性的患者血液和组织中的CLL死亡率更高，因此长期依鲁替尼治疗可使可测量的残留疾病水平更低。该试验已在www.clinicaltrials.gov上注册，注册号为#NCT01752426。
Zotero 插件